Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 17 18 19 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters 2020-01-13
Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal RnD 2020-01-13
Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx 2020-01-13
Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones 2020-01-13
MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement 2020-01-13
NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF 2020-01-10
NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders 2020-01-10
NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group 2020-01-10
NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C $22m led by existing investors BIVF + PPF Group wih all private investors 2020-01-10
Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi 2020-01-09
Bayer–Evotec: drug discovery services, 201001–202412 collab expansion women’s health €16.5m upfront + research cost + milestones >€330m drugs for PCOS 2020-01-09
Bayer–Exscientia: AI-based drug discovery, 202001–202312 collab identification lead structures for drugs to treat cardiovascular diseases + cancers 2020-01-09
Cunesoft–Phlexglobal: investment, 202001 acquisition of Cunesoft GmbH by Phlexglobal 2020-01-08
Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures 2020-01-08
Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund 2020-01-08
Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund 2020-01-08
Immunic–Daiichi Sankyo: IMU-856, 202001– license excl ww €na option exercised by Immunic AG 2020-01-08
Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve 2020-01-08
Wellington Partners–MC Services: public relations, 202001 service existent by MC Services 2020-01-08
Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform 2020-01-07
CytomX Therapeutics–Genedata: bioinformatics, 202001– supply license for Genedata Bioprocess platform to CytomX Therapeutics 2020-01-07
MiNA Therapeutics–Trophic Communications: public relations, 202001 service existent by Trophic Communications 2020-01-07
VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors 2020-01-07
VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors 2020-01-07
VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures 2020-01-07
VectivBio–WPP: public relations, 202001 service existent by Glover Park Group 2020-01-07
Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence 2020-01-07
Bruker–Adeptrix: MS-based immunoassays, 202101– collab developm BAMS assays on Bruker MALDI-MS systems 2020-01-06
Bayer–Daré Bioscience: contraceptives, 202001– license excl for US for hormone-free monthly vagial contraceptive 2020-01-01
Innerspace–High-Tech Gründerfonds: investment, 2020 seed financing round incl investor HTGF 2020-01-01
Innerspace–MAD Ventures: investment, 2020 seed financing round incl investor MAD Ventures GmbH 2020-01-01
Innerspace–SEVERAL: investment, 2020 seed financing round with MAD Ventures + HTGF 2020-01-01
KLIFO–Gilde Investment: investment, 202105 acquisition of majority share in KLFIO A/S by Gilde Healthcare 2020-01-01
MediServ–KLIFO: investment, 2020 acquisition of MediServ by KLIFO A/S 2020-01-01
Tecan–Labforward: laboratory software, 2020– collab integration of Tecan detection devices with Labfolder LIMS 2020-01-01
TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine 2020-01-01
Vaderis Therapeutics–Medicxi: investment, 2020 Series A financing CHF18m from Medicxi 2020-01-01
Aeovian Pharmaceuticals–Evotec: investment, 201912 investment existent Evotec owns 5.83% of voting rights 2019-12-31
Autobahn Labs–Evotec: investment, 201912 investment existent Evotec owns 33.33% of voting rights 2019-12-31
Blacksmith Medicines–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights 2019-12-31
Breakpoint Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 48.6% of voting rights 2019-12-31
Carrick Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 4.29% of voting rights 2019-12-31
Celmatix–Evotec: investment, 201912 investment existent Evotec owns 25.02% of voting rights 2019-12-31
Eternygen–Evotec: investment, 201912 investment existent Evotec owns 24.97% of voting rights 2019-12-31
Exscientia–Evotec: investment, 201912 investment existent Evotec owns 23.21% of voting rights 2019-12-31
Fibrocor Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 16% of voting rights of Fibrocor LLP 2019-12-31
Forge Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights 2019-12-31
FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights 2019-12-31
Immunitas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 6.44% of voting rights 2019-12-31
Topas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 28.44% of voting rights 2019-12-31
Vico Therapeutics–Bellevue: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pureos Bioventures 2019-12-31
Vico Therapeutics–Eurazeo: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Idinvest Partners 2019-12-31
Provecs–NONE: investment, 201912–202001 bankruptcy AG Hamburg 67g IN 290/19 insolvency + dissolution Provecs Medical GmbH 2019-12-30
Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc 2019-12-20
Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors 2019-12-20
Nagi Bioscience–NEST Pension Fund: investment, 201912 seed financing round totalling CHF1.8m incl investor NEST Pension Fund 2019-12-20
Nagi Bioscience–OTHER: investment, 201912 seed financing round totalling CHF1.8m incl private investors from CH + US 2019-12-20
Nagi Bioscience–SEVERAL: investment, 201912 seed financing round CHF1.8m with investiere + ZKB + NEST Pension Fund + private investors from CH + US 2019-12-20
Nagi Bioscience–Verve Capital Partners: investment, 201912 seed financing round totalling CHF1.8m incl investor investiere 2019-12-20
Nagi Bioscience–Zürcher Kantonalbank: investment, 201912 seed financing round totalling CHF1.8m incl investor ZKB 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
Kinnate Biopharma–Nextech: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd 2019-12-19
Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman 2019-12-19
Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines 2019-12-19
BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi 2019-12-18
Hitachi–Showa Denko: investment, 201912–202004 acquisition of Hitachi Chemical for JPY964b ($8.8b) 2019-12-18
Novartis–Voluntis: digital therapeutics, 201912–collab developm digital therapeutics using Theraxium Oncology platform for breast cancer 2019-12-18
BioNtech–EU (govt): credit, 201912– EIB/EFSI loan €50m to support cancer therapies RnD 2019-12-17
Cellestia Biotech–SEVERAL: investment, 201912 financing round Series B CHF20m from FC Capital + PPF Group + Partners Investment + private investors 2019-12-17
Resistell–SEVERAL: investment, 201912 financing round Series A CHF3.5m 2019-12-17
3SBio–Numab: antibody cancer drug, 201912– collab developm + commercialisation with Sunshine Guojian for multi-specific Abs in Greater China 2019-12-12
Numab–3SBio: investment, 201912–202003 financing round Series B totalling CHF22m incl CHF15m from new investor 3SBio/Sunshine Guojian 2019-12-12
Numab–Eisai: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Eisai Co Ltd 2019-12-12
Numab–Mitsubishi: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Mitsubishi UFJ Capital Co Ltd 2019-12-12
Numab–PERSON: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Daniel Vasella 2019-12-12
Numab–SEVERAL: investment, 201912–202003 financing round Series B CHF22m incl €15m from new investor 3SBio/Sunhine Guojian 2019-12-12
Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) 2019-12-10
ImmunOs Therapeutics–Bernina BioInvest: investment, 201912 financing round Series totalling CHF15m incl co-investor Bernina BioInvest Ltd 2019-12-10
ImmunOs Therapeutics–BioMedPartners: investment, 201912 financing round Series A totalling CHF15m incl co-lead investor BioMedPartners 2019-12-10
ImmunOs Therapeutics–Pfizer: investment, 201912 financing round Series A totalling CHF15m incl co-lead investor Pfizer Ventures 2019-12-10
ImmunOs Therapeutics–Redalpine: investment, 201912 financing round Series A totalling CHF15m incl co-investor Redalpine 2019-12-10
ImmunOs Therapeutics–Schroders: investment, 201912 financing round Series A totalling CHF15m incl co-investor Schroder Adveq 2019-12-10
ImmunOs Therapeutics–SEVERAL: investment, 201912 financing round Series A CHF15m co-led by Pfizer Ventures + BioMedPartners 2019-12-10
ImmunOs Therapeutics–Wille Finance: investment, 201912 financing round Series A totalling CHF15m incl co-investor Wille Finance AG 2019-12-10
Schauenburg–JP Scientific: SPE technology, 201912– ww commercial license + supply to Markes from JP Scientific Ltd 2019-12-10
Algiax Pharmaceuticals–SEVERAL: investment, 201912 financing round €5.5m incl new investor Occident 2019-12-09
EMBL–Bruker: microscope, 201912 supply existent early customer EMBL for new Luxendo TruLive3D Imager 2019-12-09
Synthorx–Sanofi: investment, 201912–202001 acquisition $2.35b cash tender offer at $68/share 2019-12-09
Biocom–OTHER: investment, 201912–202003 capital increase nominal capital increase by €800k to €1m 2019-12-08
BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications 2019-12-06
Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services 2019-12-06
4Teen4 Pharmaceuticals–Brandenburg (govt): investment, 201912 financing round Series A totalling €6.9m incl lead investor Brandenkapital GmbH 2019-12-05
4Teen4 Pharmaceuticals–SEVERAL: investment, 201912 financing round Series A €6.9m led by Brandenkapital GmbH with private investors + business angels 2019-12-05
Biological Industries (IL)–Sartorius: investment, 201912 acquisition of just over 50% for €45m in cash with option to acquire further 20% 2019-12-05
ImCheck Therapeutics–Dentons: legal services, 201912 supply service Dentons Europe acted as legal counsel for €48m Series B round of ImCheck 2019-12-04
next pagenext page 1 2 3 ... 17 18 19 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] Fighting Customers 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top